Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. [electronic resource]
Producer: 20150226Description: 1193-202 p. digitalISSN:- 1530-0285
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Blotting, Western
- Cell Line
- Fibroblasts -- metabolism
- Gene Expression
- Hepatocyte Growth Factor -- metabolism
- Humans
- Imidazoles -- therapeutic use
- Immunohistochemistry
- Indoles -- therapeutic use
- Melanoma -- drug therapy
- Oximes -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- RNA, Messenger -- genetics
- Real-Time Polymerase Chain Reaction
- Skin -- cytology
- Skin Neoplasms -- drug therapy
- Sulfonamides -- therapeutic use
- Transfection
- Vemurafenib
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.